This is an important victory for public health. The Sanofi laboratory obtained last Wednesday the first authorization to market its Dengvaxia vaccine against the dengue virus in Mexico. “When Sanofi undertook, 20 years ago, to develop a vaccine against dengue with the scientific community and public health actors, locally and internationally, it was with the intention of developing an innovative vaccine. to tackle this global public health need, ”said Dr Olivier Brandicourt, CEO of Sanofi, in the press. An authorization application for the European Union is scheduled for early 2016. Almost half of the world's population is exposed to the risk of this viral infection, according to the World Health Organization (WHO).
5,329 total views
No comments